Real world clinical insight
"In the management of ALK-positive non-small cell lung cancer, the central nervous system has historically acted as a sanctuary site. Even when early-generation TKIs effectively controlled systemic disease in the lungs, they often failed to penetrate the blood-brain barrier, leaving the brain vulnerable to metastatic spread. The development of third-generation molecules like Lorlatinib represents a critical shift in our clinical protocols. By effectively crossing the BBB, we can now induce deep intracranial responses and target complex ALK resistance mutations (such as G1202R).